What treatment is commonly indicated for patients with hemolytic uremic syndrome who do not respond to supportive care?

In the context of hemolytic uremic syndrome (HUS), particularly in cases associated with atypical forms or those due to complement dysregulation, the use of eculizumab is commonly indicated when patients do not respond adequately to supportive care. Eculizumab is a monoclonal antibody that inhibits the complement protein C5, which plays a significant role in the pathophysiology of atypical HUS. This treatment targets the underlying complement-mediated processes that can lead to renal impairment and hemolytic anemia in these patients.

Supportive care for HUS often includes hydration, management of electrolyte imbalances, and monitoring renal function; however, when these measures fail to improve the clinical condition, eculizumab can be critical in preventing further renal damage and managing symptoms effectively.

The other treatment options mentioned may have their uses in different contexts or types of illnesses, but they are not the go-to therapies for patients with HUS when supportive care is insufficient, making eculizumab the most appropriate choice in this scenario.